UBS O'Connor’s Roivant Sciences ROIV Stock Holding History

UBS O'Connor’s Portfolio ROIV Stock Details ROIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-50,000	Closed	-$3.75K	–	590
2023 Q4	$3.75K	Buy	+50,000	New	+$487K	﹤0.01%	485

Other funds holding ROIV

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

PSC

Patient Square Capital Menlo Park, California $646M AUM 291.07% 1-Year Est. Return

UBS O'Connor's ROIV Position: Q2 2025 in Review

UBS O'Connor sold out of Roivant Sciences (ROIV) in Q2 2025, closing a stake of 42,819 shares — an estimated $432K sold.

UBS O'Connor first reported a position in ROIV in Q4 2022 and held it in 10 quarters. The position peaked at $2.23M in Q4 2023. 338 funds tracked by Wall St. Rank hold ROIV as of Q2 2025.

UBS O'Connor reported no remaining Roivant Sciences position as of Q2 2025 after selling out during the quarter.
UBS O'Connor sold 42,819 Roivant Sciences shares in Q2 2025, an estimated $432K.
UBS O'Connor first reported a position in Roivant Sciences in Q4 2022 and held it in 10 quarters.
UBS O'Connor's Roivant Sciences position peaked at $2.23M in Q4 2023.
338 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2025.

Based on UBS O'Connor's 13F filing for Q2 2025, filed 14 Aug 2025.